company background image
ANP

Antisense Therapeutics ASX:ANP Stock Report

Last Price

AU$0.086

Market Cap

AU$57.2m

7D

0.6%

1Y

-56.2%

Updated

01 Oct, 2022

Data

Company Financials +
ANP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANP Stock Overview

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia.

Antisense Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Antisense Therapeutics
Historical stock prices
Current Share PriceAU$0.086
52 Week HighAU$0.35
52 Week LowAU$0.073
Beta1.2
1 Month Change-18.57%
3 Month Change4.27%
1 Year Change-56.15%
3 Year Change-11.86%
5 Year Change151.47%
Change since IPO-96.44%

Recent News & Updates

Aug 26
We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ANPAU PharmaceuticalsAU Market
7D0.6%-0.6%-1.7%
1Y-56.2%-23.6%-10.8%

Return vs Industry: ANP underperformed the Australian Pharmaceuticals industry which returned -23.6% over the past year.

Return vs Market: ANP underperformed the Australian Market which returned -10.8% over the past year.

Price Volatility

Is ANP's price volatile compared to industry and market?
ANP volatility
ANP Average Weekly Movement14.7%
Pharmaceuticals Industry Average Movement10.7%
Market Average Movement9.4%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market4.2%

Stable Share Price: ANP is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: ANP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aMark Diamondhttps://www.antisense.com.au

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company’s product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.

Antisense Therapeutics Limited Fundamentals Summary

How do Antisense Therapeutics's earnings and revenue compare to its market cap?
ANP fundamental statistics
Market CapAU$57.18m
Earnings (TTM)-AU$5.81m
Revenue (TTM)AU$1.78m

32.3x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANP income statement (TTM)
RevenueAU$1.78m
Cost of RevenueAU$65.68k
Gross ProfitAU$1.71m
Other ExpensesAU$7.52m
Earnings-AU$5.81m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0087
Gross Margin96.30%
Net Profit Margin-326.89%
Debt/Equity Ratio0%

How did ANP perform over the long term?

See historical performance and comparison